Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

CGTN: China protects lives, shares experience in global COVID-19 fight


News provided by

CGTN

15 Jan, 2023, 23:40 GMT

Share this article

Share toX

Share this article

Share toX

BEIJING, Jan. 15, 2023 /PRNewswire/ -- Chinese people are embracing a bustling winter after the country downgraded its COVID-19 management policies. 

It's a breakthrough in the country's three-year fight against the pandemic, but challenges still lie ahead. 

Along the journey, China went all out to protect its people and shared its valuable experience with the world.

Lives protected

China has seen declining numbers of fever patients, emergency visits and critical COVID-19 cases across the country, according to statements at a press conference held by the State Council joint COVID-19 prevention and control mechanism on Saturday.

The number of critical cases in hospitals peaked on January 5 at 128,000, and dropped to 105,000 on January 12, said Jiao Yahui, head of the Bureau of Medical Administration under the National Health Commission (NHC).  

To strike a balance between saving lives and ensuring economic activity, China's COVID-19 policies have bought time in which greater protections have been developed and the virus has become less deadly.

As of January 13, over 661 million confirmed COVID-19 cases and over 6.7 million related deaths had been reported globally, according to the World Health Organization (WHO).

China's death rate per 100,000 people stood at 2.29 as of January 13, according to the WHO, which is 1/37 of the global average and 1/143 of the United States.

The case fatality rate in China was 0.31 percent, far below the 1.01 percent global average and the 1.09 percent of the U.S. as of January 13, data from the WHO showed.

Putting "people first, life first" at the core of COVID-19 policymaking, China owes its low death rate to its strict prevention and control measures in the past three years.

"Based on the global average infection rate, China has prevented about 47.84 million infections and 950,000 deaths," said Wu Zunyou, chief epidemiologist of the Chinese Center for Disease Control and Prevention, at a public meeting in November of 2021.

At that time, Wu presented the figures to explain why China had to stick to its dynamic zero policy even though the U.S. and some European countries had relaxed their prevention and control strategies.

If projected using the death rate in the U.S., China has prevented over 3 million deaths, Wu added.

Experience shared

When the outbreak first occurred in 2020, China took strong measures to prevent the virus' further transmission by shutting exit channels, which created valuable space for the international community to make preparations.

China has been consistently sharing its information on the epidemic. It promptly reported the outbreak to the WHO, shared the genome sequencing results with the world and published its control and treatment protocols. All these moves facilitated COVID-19 prevention and control in the international community, and the research and development of vaccines and testing tools.

In order to share its experience, the country organized over 300 exchange events on epidemic control and medical treatment with over 180 countries and regions and more than 10 international organizations, according to the NHC. In addition, 37 medical teams were sent to 34 countries to help out at the front line.

During the past three years, China has updated 10 pilot editions of COVID-19 diagnosis and treatment protocols. As traditional Chinese medicine (TCM) has been found to be beneficial in the treatment of the disease, China has held over 100 video exchange and live-streaming events to introduce TCM diagnosis and treatment methods to more than 150 countries and regions.

Medical tools developed

During the precious low-infection window its policies created, China worked against time to develop COVID-19 drugs while promoting vaccination.

Both domestically developed and imported drugs have been approved for emergency use by China's medical products regulator. More than 10 oral drugs for COVID-19 treatment are being researched and developed in China.

So far, 13 COVID-19 vaccines have been approved by the National Medical Products Administration for conditional marketing or emergency use in China. They can be inhaled or given to people through injection and nasal spray.

To build an immunity barrier against the virus, the Chinese government provided free vaccines for all and continued to improve the vaccination rate. The number of people in China fully vaccinated accounted for over 90 percent of the total population as of mid-December 2022.

Meanwhile, over 4.6 million Chinese citizens living and working in 180 countries have benefited from the "Spring Sprout" vaccine campaign, China's global campaign to inoculate its nationals living and working abroad, according to the Ministry of Foreign Affairs.

China was the first country to announce it would make its COVID-19 vaccine a global public good. It also took the lead in waiving intellectual property rights for COVID-19 vaccines and conducting joint production with developing countries. The country has offered more than 2.2 billion doses of vaccines to over 120 countries and international organizations.

It also provided hundreds of billions of epidemic control materials to 153 countries and 15 international organizations.

https://news.cgtn.com/news/2023-01-15/China-protects-lives-shares-experience-in-global-COVID-19-fight--1gBV8M2PGGA/index.html

Modal title

Also from this source

CGTN: What Drives Chinese Modernization?

CGTN: What Drives Chinese Modernization?

The Chinese modernization is a unique and transformative process that has redefined the concept of development in the 21st century. The unique and...

CGTN: Second China-Central Asia Summit eyes a closer China-Central Asia community with a shared future

Following the announcement by China's Foreign Ministry that President Xi Jinping will attend the second China-Central Asia Summit in Astana,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Infection Control

Infection Control

Publishing & Information Services

Publishing & Information Services

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.